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The current SARS-CoV-2 (coronavirus) outbreak has reached pandemic 
proportions with a large global imprint. In December 2019, COVID-19 was first 
reported in Wuhan, Hubei Province, China and has continued largely unabated. 
The SARS-CoV-2 (coronavirus) is much talked about currently; however, it is 
worth noting that there are several different coronaviruses known to man, with 
most of them being responsible for causing illness in animals. Seven (7) types of 
coronaviruses are identified as causing illnesses in humans. Of the seven human 
coronavirus infections, four involve mild upper respiratory tract complaints that 
produce slight symptoms of the common cold. Conversely, the other three human 
coronavirus infections present more severe consequences as recently demonstrated 
by the SARS-CoV-2. These deadly outbreaks of pneumonia can have consequences 
that are far-reaching and are global in nature. SARS-CoV was the first new viral 
pandemic of the 21st century. It had its beginnings in southern China during 
November 2002 having started mysteriously; It was contained in 2004 after having 
spread to five continents and thirty-three countries, infecting approximately 8000 
people. MERS-CoV the virus that the causes Middle East respiratory syndrome 
(MERS) was first identified in 2012 in Saudi Arabia and Jordan and has since 
registered roughly 2,220 confirmed cases and 790 deaths.
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1. Introduction
Coronavirus (CoV) is one of the leading pathogens primarily targeting that the 
human respiratory system [1]. Earlier outbreaks of coronaviruses include the severe 
acute respiratory syndrome (SARS)-CoV and the Middle East respiratory syndrome 
(MERS)-CoV which have been formerly considered as a serious threat to public 
health [2]. The first iteration of coronavirus was identified in the mid-1960s and 
categorized into four separate subfamilies: α−/β−/γ−/δ-Coronavirus. Alpha and 
beta-coronaviruses predominantly causes infection in mammals, whereas gamma 
and delta-coronaviruses primarily infect birds [3]. A new contagious coronavi-
rus is presently holding much of the worldwide population hostage. This virus, 
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SARS-CoV-2, which causes the COVID-19 disease, emerged in Hubei, China and 
has spread to most countries with ongoing devastating effects [4].
Since the era of the pneumonic plague, emergent respiratory infections have 
enthralled the scientific and Public communities’ and more recently have mani-
fested in popular films depicting airborne viral outbreaks [5]. This has led to 
deliberations pertaining to the possibility for respiratory spread of these infections 
[6]. Although numerous emerging agents can exhibit respiratory involvement, 
this chapter will focus on emerging pathogens that involve the respiratory system 
and focus on 3 agents that exhibit a range of characteristics of emerging diseases: 
SARS-CoV, MERS, and SARS-CoV-2.
2. SARS-CoV
2.1 Etiology, epidemiology, and clinical presentation
Severe acute respiratory virus (SARS) is a deadly pulmonary infection caused 
by the SARS coronavirus (SARS-CoV), first reported in Guangdong Province, 
China, in November 2002 [7]. The emergence of SARS-CoV signaled the first time 
the public, as well as numerous scientists, observed this cluster of viruses, and 
its potential to cause severe infections and death in humans [8]. By July 3, 2003, 
SARS global infections were 8439 cases of which 812 were fatal [9]. This prompted 
a full-bodied international response estimated at roughly 40 billion dollars which 
aided in containing the outbreak [10]. By the close 2004 there were no new reported 
cases [9, 10]. Genetic classification indicates that the introduction into the human 
population took place from civets or other mammals found in live-animal markets 
of China [9]. Furthermore, it is prevailingly considered that SARS-CoV originated 
in a colony of horseshoe bats in southern China, with civets acting as the intermedi-
ate amplifying and transmitting host to humans [11].
3. SARS-CoV infection in humans
SARS-CoV is an airborne virus transmissible between humans through small 
respiratory droplets, in a similar manner to influenza [6]. SARS-CoV can also be 
spread indirectly via surfaces that have been touched by someone who is infected 
with the virus, and by close interactions with infected individuals acting as so-
called “super spreaders” [6]. The incubation period of SARS-CoV is generally 
2–7 days, but infected persons may present symptoms as long as 10 days after infec-
tion [6]. Several epidemiological studies conducted during the outbreak identified 
numerous deaths occurring disproportionately among the elderly, and individuals 
who were immunosuppressed. At the onset of SARS-CoV illness, patients present 
with flu-like symptoms typically non-specific, with mild respiratory symptoms 
identified as most common in some cases, while other symptoms included rash, 
malaise, fever, and myalgia [12, 13]. Approximately 70% of the SARS-CoV patients 
experience shortness of breath and lingering or persistent fever, while clinical 
improvements were observed in 30% patients after the first week [14]. Intensive 
care treatments such mechanical ventilation was required by about 20 to 30% of 
SARS-CoV patients [14, 15]. Individuals 12 years of age and younger displayed 
limited severe disease manifestations [6, 13, 16]. Prognostic studies indicate greater 
risk of severe outcomes associated with increased age, high pulse, and lactate 
dehydrogenase (LDH) levels [7, 17, 18].
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4. Pathological changes and clinical diagnosis in SARS-COV infection
Histopathologic data existing on SARS-CoV patients have been mostly deter-
mined from autopsy cases. Pathological lesions in certain organs of SARS-CoV 
victims, such as the lungs and intestines, have been extensively studied [1, 4]. The 
primary pathological change in SARS-CoV patients occurs in the lungs [4, 6]. Gross 
examination of the lungs revealed edematous, heavy lungs weighing up to 2100 g 
with several areas of extensive consolidation (Figure 1) [1, 4].
Histopathologic data for SARS-CoV of infected lungs characteristically dis-
played diffuse alveolar damage [DAD] [19, 20]. Through the initial period of the 
disease (7 to 10 days), SARS lungs exhibited the following characteristics of acute 
exudative DAD: 1) Widespread edema, 2) desquamation of alveolar epithelial cells, 
3) formation of hyaline membrane, 4) collapse of alveoli, and 5) fibrous tissue in 
alveolar spaces (Figure 2) [6, 12, 19, 21, 22].
In SARS cases of lengthier disease duration, fibrous organization features of 
DAD were visible after approximately 10–14 days. These features included intersti-
tial and airspace fibrosis and pneumocytic hyperplasia [12, 23, 24]. The more exten-
sive the disease period, the more widespread the fibrous organization of the lung 
tissue [14, 25, 26]. Dense septal and alveolar fibrosis were exhibited in SARS cases 
with duration of more than 2 to 3 weeks [12, 19, 23, 24]. The overall histological data 
presentation of SARS lung infection is non-specific and dependent on symptom 
onset; Acute DAD is most frequently associated with early phase disease (<10 days) 
[6, 27]. Furthermore, there is limited documentation on the pathologic demonstra-
tion of SARS-CoV in living patients, since the bulk of patient tissue samples were 
taken from autopsy [1, 4, 6].
The predominant changes involving SARS-CoV cases have been visceral and 
involve severe pulmonary changes [1, 19]. Accurate and easily implementable 
diagnostics formed an essential part of SARS-CoV disease control, due to the non-
specific nature of the infection and its rapid spread. Following the initial disease 
outbreak, many laboratories rapidly developed SARS-CoV reverse transcription 
polymerase chain reaction test (RT-PCR) analyzes, to detect viral RNA. These tests 
have numerous advantages over traditional RT-PCR tests [28].
Real-time RT-PCR assays use amplification primers and internal probes as a 
result, can be designed to be extremely precise for SARS-CoV RNA [6]. Real-time 
Figure 1. 
SARS gross morphology of the lung [19]. Images ©John Wiley and Sons Ltd. as cited.
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RT-PCR analyzes can be extremely sensitive, with steady detection limits of 
between 1 and 10 SARS-CoV RNA copies per reaction [6, 29]. They can be com-
pleted quicker than traditional RT-PCR analyzes with reduced risk of contamina-
tion in the laboratory. Real-time RT-PCR assays often times give a very accurate 
estimate of the viral load present in a sample [29].
5. MERS-CoV
5.1 Etiology, epidemiology and clinical presentation
The Middle East respiratory syndrome coronavirus (MERS-CoV or MERS) was 
first identified in September 2012 in a fatal case of severe respiratory failure in a 
Saudi Arabian patient [30, 31]. Previous cases were retrospectively acknowledged 
from an outbreak of severe respiratory illness in Jordan in 2012 [32]. In contrast 
to the rapid spread and subsequent latency of SARS-CoV, MERS-CoV has moved 
continuously through the Arabian Peninsula and generated sporadic outbreaks in 
countries where infected persons have traveled [6]. As of January 2020, there have 
been 2519 laboratory-confirmed cases of MERS, and 866 associated deaths (case-
fatality rate: 34.3%) reported globally [32].
A significant number of cases has been identified in Saudi Arabia and to a lesser 
extent the United Arab Emirates (UAE), Qatar and Jordan [33]. While the close rela-
tionship to numerous bat coronaviruses suggests a bat-related origin, overwhelming 
molecular and serological evidence points to the involvement of dromedary camels 
in the transmission of MERS-CoV to a human host [34]. While transmission from 
ancestral bats to camels cannot be excluded, and camels may have introduced the 
virus into human populations, the majority of reported MERS-CoV cases have 
ensued from human-to-human nosocomial transmission [6, 33].
A hospital outbreak was reported in Saudi Arabia with a cluster of six cases; 
Three of the cases were healthcare workers, two were patients (one of whom died) 
and one was a visitor. Another instance involved an ill patient admitted to a Korean 
Figure 2. 
(A) Alveoli filled with desquamated epithelial cells. (B) Formation of hyaline membrane (H&E, original 
magnification ×200).
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hospital which led to an outbreak of 186 infections including 36 fatal cases [35]. 
Person-to-person transmission has also been identified within households, where 
the highest risk of transmission involves patient respiratory secretions and indi-
viduals being within close proximity with each other. Individuals exhibiting signs 
and symptoms or other epidemiological characteristics suggestive of MERS should 
be promptly quarantined and tested for viral infection [32, 35].
6. MERS-CoV infection in humans
The clinical manifestation for MERS-CoV infection varies from asymptomatic/
mild to severe disease. Generally, individuals with chronic comorbid conditions 
(diabetes, heart disease) and elderly patients are at increased risk for development 
of respiratory failure [35]. Although infection is commonly associated with respira-
tory disease, in some rare cases viral RNA has been discovered in blood, stool and 
urine signifying a systemic infection [33, 35].
Notwithstanding the increased mortality related to symptomatic cases, research 
studies have shown that roughly 25% of patients infected with MES-CoV are 
asymptomatic [36]. A seroepidemiological analysis of over 10,000 infected samples 
from Saudi Arabia revealed positive antibodies in approximately 0.15% of patients. 
Individuals with some level of camel-exposure had an increased likelihood of 
positive serology [33, 35]. Clinical symptoms are non-specific, and patients have 
reported an expansive range of diverse indicators including chest pain, fever, cough, 
myalgia, sore throat, shortness of breath, vomiting and diarrhea [32]. In more 
severe cases, mechanical ventilation is required for patients who are presented with 
acute hypoxic respiratory failure [15, 31]. Fatal outcome of MERS-CoV infection 
have been associated with underlying comorbidities such as hypertension, diabetes 
mellitus type II, obesity, and cardiac disease [37]. MERS-CoV infection has an 
incubation period that ranges from 2 to 14 days [30]. Signs and symptoms usually 
appear well before the patient reaches a detectable viremia i.e. the virus is present 
in the patients’ bloodstream [30, 37]. Neurological sequelae, and gastrointestinal 
distress have also been documented in addition to these respiratory symptoms [37].
7. Pathological changes and clinical diagnosis in MERS-COV infection
The understanding of the pathological findings related to MERS-CoV infection 
have relied on a paucity of autopsy cases. Notwithstanding the limited number of 
autopsy cases, several studies have assessed the pathological features of MERS-CoV 
infection in human tissue. The pathogenesis of MERS-CoV infection in human tis-
sue ex vivo revealed exudative diffuse alveolar damage (DAD) with hyaline mem-
branes, interstitial pneumonia (which was primarily lymphocytic), pulmonary 
edema, multinucleate syncytial cells, and type II pneumocyte hyperplasia [38]. 
Researchers also observed bronchial submucosal gland necrosis in diseased lung 
tissue, where these bronchial lesions make up the pathologic origin for respiratory 
failure and radiologic anomalies of MERS-CoV infection [38]. Some of the cells in 
the lungs targeted by the MERS-CoV infection include: pneumocytes, multinucle-
ated epithelial cells, and bronchial submucosal gland cells [39]. Microstructurally, 
viral particles were discovered in the pulmonary macrophages, pneumocytes, renal 
proximal tubular epithelial cells and macrophages infiltrating the skeletal muscles 
[38, 40]. Consistent with the microstructural results in the kidney, renal biopsies 
revealed acute tubulointerstitial nephritis and acute tubular sclerosis with protein-
aceous cast formation [40].
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Researchers discovered comparable replication of kinetics and cellular tropism 
in a study comparing the replication of camel-isolated MERS-CoV strains to 
human-isolated MERS-CoV strains. Non-ciliated bronchial epithelium and alveolar 
epithelial cells including type II pneumocytes were infected by all strains. It is 
important to note that no infection of the pulmonary macrophages was present 
[39]. Infection of several cell types including vascular endothelial cells, renal tubu-
lar cells, and podocytes was established in studies examining kidney explants [41]. 
Exploratory infection of small intestine tissue samples with MERS-CoV confirmed 
that infection was restricted to the surface enterocytes and formation of syncytial 
cells [6]. It has been observed that infected patients shed virus in their urine and 
stool, which is consistent with these findings.
RT-PCR has functioned as the main clinical laboratory diagnostic test through-
out transmission events. Critical to the success of these tests is an understanding 
of the viral kinetics and tissue tropism discovered in MERS-CoV cases. Numerous 
studies have acknowledged that lower respiratory tract samples contain the high-
est viral loads, while upper respiratory swabs, whole blood or serum, feces, and 
urine may also contain significant viral load [35]. Samples from the upper respira-
tory tract, urine and blood may offer further diagnostic usefulness by delivering 
a convenient sample type, notwithstanding 10 to 100 times lower virus levels. 
Measurable viremia at the point of diagnosis has been linked with an increase in 
patient death due to the necessity for mechanical ventilation, despite blood only 
being positive in approximately one-half to one-third of cases [42]. The reduced 
viremia rate in MERS-CoV samples in comparison to SARS-CoV is significantly 
different, where RT-PCR on blood can be beneficial for preliminary diagnosis 
and is normally the primary positive site identified. Analyses of upper and lower 
respiratory samples as well as blood samples for MERS-CoV patients, has shown 
that it may benefit in maximizing the sensitivity while also stratifying risk [34]. 
Two RT-PCR testing approaches were approved for emergency use authorization by 
the FDA during the MERS-CoV outbreak: both targeted a region upstream of the 
envelope gene (principal target of the humoral immune response). Of these two 
tests, one additionally targets a specific region of the ORF1a gene, while the other 
targets two regions inside the nucleocapsid gene [6].
MERS-CoV serology tests share comparable kinetics to that of SARS-CoV 
infections. About 2–3 weeks following the onset of symptoms, a significant num-
ber of patients develop measurable levels of IgM and IgG antibodies. However, in 
many cases the detection of IgG has superior diagnostic value when compared to 
IgM [34]. Some researchers posit that if serologic testing is used to detect current 
infection, “a neutralization assay and 4-fold increase in titer after 14 days should 
be used to confirm a specific immune response” [6, 42]. Disease severity may 
affect antibody responses as numerous studies have established; PCR-positive 
patients exhibiting only mild disease symptoms often do not generate measurable 
quantities of antibodies, especially when monitored during the post-acute phase of 
disease [34].
8. SARS-CoV-2
8.1 Etiology, epidemiology, and clinical presentation
The coronavirus (SARS-CoV-2) (also known as the novel coronavirus) outbreak 
has reached pandemic proportions with a large global footprint [43, 44]. In late 
December 2019, SARS-CoV-2 was first reported in Wuhan, Hubei Province, China 
among clusters of patients with pneumonia of unknown etiology [43, 44]. In early 
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January 2020, the National Health Commission of People’s Republic of China 
released information regarding the causative agent of an enigmatic pneumonia 
identified as a novel coronavirus (SARS-CoV-2). The novel coronavirus (SARS-
CoV-2) was verified by several independent laboratories located in China [45, 46]. 
The World Health Organization (WHO) provisionally named the causative virus as 
2019 novel coronavirus [2019-nCoV/SARS-CoV-2] [46]. Coronaviruses are known 
to cause respiratory, hepatic, and neurologic diseases and are generally spread 
among humans and animals [3]. The SARS-Cov-2 virus is illustrated by a spherical 
shape, and a characteristic “crown” appearance, and they belong to the family of 
coronaviruses of positive-stranded RNA viruses [47].
Genetically, SARS-CoV-2 has a closer resemblance to SARS-CoV than the 
Middle East respiratory syndrome coronavirus [MERS-CoV] [48]. Nevertheless, 
the span of the incubation period, clinical severity, and transmissibility of SARS-
CoV-2 differs from SARS-CoV [49]. Public health and government efforts aimed 
at curbing the spread by implementing social practices through social distancing, 
mask wearing, isolating/quarantining and non-pharmacological and preventive 
treatments for psychophysical wellbeing, has been relatively successful in part, 
but SARS-CoV-2 has continued to increase globally [50, 51]. By the end of January 
2021, SARS-CoV-2 accounted for more than two million deaths and more than 
100 million confirmed cases of the disease [52]. Radiologically, SARS-CoV-2 has 
distinctive imaging features that constitute a visual identity. Besides, SARS-CoV-2 
negatively impacts other organs in addition to the lungs. As a result of these devel-
opments, SARS-CoV-2 has grown exponentially with nearly 2000 articles being 
published per week [50].
9. SARS-CoV-2 infection in humans
SARS-CoV-2 infections are variable in nature, with some infections being 
asymptomatic with others causing minor to moderate illness with respiratory and 
flu-like symptoms, including sore throat, fever, chills, and cough [53]. Injury, 
inflammation and ensuing respiratory distress in SARS-CoV-2 patients occurs as a 
result of the SARS-CoV-2 spike protein binding to human angiotensin I-converting 
enzyme 2 (hACE2) predominantly targeting the virus to type II pneumocytes 
inside the lung [54, 55]. A substantial number (approximately 20%) of patients also 
develop severe infection and multi-organ failure which necessitates intensive care 
with mechanical ventilation or extracorporeal membrane oxygenation [50, 53]. In 
some cases, SARS-Cov-2 infection can be deadly, with a case fatality rate of ~5%. 
The incubation period of SARS-CoV-2 is generally 5–7 days, but the symptoms of 
infection may present itself well after that period [56]. The phase from the onset of 
symptoms to fatality usually varies from 7 to 40 days with a median of 14 days [57]. 
This phase is dependent on the patients’ age, and the status of their immune system.
Similarities in the symptoms between SARS-CoV-2 and earlier beta-coronavirus 
such as fever, dry cough, and dyspnea are distinctive [50]. However, there are 
distinctive features presented by SARS-CoV-2 which involves affecting of the lower 
airway as evident by upper respiratory tract indicators like sneezing, rhinorrhoea, 
and sore throat [58]. Additionally, chest radiograph results taken upon admission, 
show an infiltrate in the upper lobe of the infected lungs, associated with increased 
difficulty breathing (dyspnea) resulting in low levels of oxygen in the blood 
(hypoxemia) [58]. Notably, while most SARS-CoV-2 patients exhibit gastrointestinal 
symptoms like diarrhea, very few MERS-CoV or SARS-CoV patients show similar 
gastrointestinal concerns. Thus, testing fecal and urine samples to exclude a poten-
tial alternative route of transmission among patients and healthcare workers [57].
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10. Pathological changes and clinical diagnosis in SARS-COV-2 infection
Nasal droplets and saliva from infected patients function as the leading route of 
SARS-CoV-2 virus communicability [59]. According to Heydarloo et al., the virus 
accesses the alveolar-type 2 cells (AT2 cells) by attaching its viral spike (S1 and S2) 
proteins to the angiotensin-converting enzyme 2 (ACE2) receptor [60]. Researchers 
found that previous iterations of coronaviruses specifically SARS-CoV, replicated more 
aggressively in alveolar-type 2 cells than in alveolar type 1 cells in the lung [38]. This is 
significant since it has been reported that there is an 80% genetic similarity between 
the SARS-CoV and SARS-CoV-2 viruses [61]. SARS-CoV-2 has an extraordinary poten-
tial for binding with AT2 cells in the lungs as shown via molecular pathways [62].
The SARS-CoV-2 pandemic continues to affect much of the world and under-
standing its clinical diagnosis is important. Data on diagnostic testing for SARS-
CoV-2 is still in its infancy, as such, understanding these tests and interpreting 
their results is imperative. The most frequently administered and dependable test 
for SARS-CoV-2 diagnosis thus far, has been the RT-PCR test completed using 
nasopharyngeal swabs. In some cases, alternative upper respiratory tract samples, 
comprising throat swabs and/or saliva have been used. Individual companies focus 
on a variety of RNA genes, with a significant number of tests affecting 1 or more of 
the envelope, RNA-dependent RNA polymerase (RdRp), and ORF1 genes [63].
In most SARS-CoV-2 patients with symptomatic infection, viral RNA in the naso-
pharyngeal swab becomes detectable as early as day 1 of symptoms and peaks within 
the first week of symptom onset. The cycle threshold (Ct) that is used to measure 
viral RNA, can be defined as “the number of replication cycles required to produce a 
fluorescent signal, with lower cycle threshold values representing higher viral RNA 
loads” [63]. A PCR positive is typically clinically reported as a Ct value of less than 
40. By week three of infection, there is usually a decline in this positivity and sub-
sequently becomes unnoticeable. In severely ill hospitalized SARS-CoV-2 patients, 
the cycle threshold values are lower than the cycle threshold values recorded in less 
severe cases. It is important to note, a “positive” PCR result reveals only the recogni-
tion of viral RNA and does not automatically suggest presence of viable virus [62]. 
It has been reported in a minority of positive test cases that viral RNA was detected 
by RT-PCR past week six. There have also been instances of a positive result being 
reported after consecutive negative PCR tests completed two days apart. Currently, 
it is unclear whether this is a testing error, reinfection, or recurrence.
SARSCoV-2 infection can also be identified indirectly by assessing the patients’ 
immune response to infection. In patients who exhibit mild to moderate symptoms, 
serological diagnosis becomes extremely important past the first two weeks of 
illness onset. Serological diagnosis is an essential means of understanding the scope 
of SARSCoV-2 infection in the community and may assist in identifying individuals 
who are immune/protected from infection.
11. Conclusion
Wide-ranging efforts to decrease transmission of SARSCoV-2 infection are 
crucial to controlling the present epidemic. Lessons learned from the SARS-CoV 
and MERS-CoV outbreaks offer, valuable experiences and insights into how to 
fight the SARSCoV-2. Specific consideration aimed at decreasing spread must be 
applied in vulnerable populations specifically health care workers, and the elderly. 
Additionally, research into the pathogenesis of human coronavirus infection is 
crucial for finding suitable therapeutic objectives. Presently, no specific antiviral 
drug is available for SARS-CoV, MERS, and SARSCoV-2.
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